![Signant-Health-Logo-Tagline-Color-(002) Signant-Health-Logo-Tagline-Color-(002)](https://vertassets.blob.core.windows.net/image/33340e9f/33340e9f-ca9c-4f18-a034-fb0bf6f1b21d/signant_health_logo_tagline_color__002_.jpg)
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics.
FEATURED CONTENT
An EDC Option You Didn’t Know You Had!
Signant Health offers the most comprehensive eClinical suite in life sciences, now featuring a recently acquired EDC/DDC solution proven in more than 3,000 clinical trials over 25+ years. Sponsors and CROs are switching to Signant Health's EDC for its ease of use, efficiency, flexibility, and superior support. Plus, study teams can choose a full-service or self-service model to accommodate the needs of any trial or program.
CLINICAL TRIAL OPTIMIZATION
Signant’s comprehensive, end-to-end clinical trial optimization solutions are fully supported by more than fifty full-time clinicians, scientists, medical practitioners, and key opinion leaders experienced in all therapeutic areas. In addition to reliable, proven solutions and scientific expertise, sponsors and CROs leverage Signant’s global scale and trial delivery expertise. Our approach to trial optimization is to ensure the best practices and best solutions are in place to help your programs succeed. Explore these resources to learn more about how this approach ensures trials generate reliable, accurate, submission-ready data.
RESOURCES & PERSPECTIVES
-
Paper Vs ePRO: Clinical Data Collection Methods
Patient-reported outcomes (PROs) assess patients' health without clinician interpretation. Traditional paper methods often result in missing data and quality issues, while electronic solutions enhance data accuracy and completeness.
-
The Case For Cognitive Assessments In Phase 1 Clinical Trials
Regulators prioritize patient-reported outcomes. Cognitive assessments in Phase 1 trials detect early drug-related cognitive effects, ensuring safety and efficacy. Signant’s CDR System® is a proven tool for this.
-
Myasthenia Gravis: Reducing Outcome Measures Variability In Trials
Myasthenia Gravis is a rare autoimmune disease often unknown to the public. This post explores MG's history, treatment progress, clinical trial challenges, and strategies to reduce outcome variability, improving patient care.
-
Subjective Measures, Objective Outcomes: Data Quality In Atopic Dermatitis Trials
Atopic Dermatitis (AD) is a prevalent skin condition. This post explores key measurement tools in AD clinical trials, specifically EASI and Total BSA, highlighting the importance of accurate measurement and strategies to improve data quality.
-
Site Perspectives On BYOD ePRO Use
This study examines participant convenience and compliance, aiming to understand and address the challenges faced by site personnel in global trials.
SUCCESS STORIES
-
RTSM And Clinical Drug Dispensation
A pharma company used Signant Health's RTSM solution in a Phase 2 schizophrenia trial to ensure drug availability, maintain study balance, prevent duplicate allocations, and manage returns and destruction of unused drugs.
-
Our Unified Platform Serves As eSource For COVID Treatment Trial
Signant Biotech optimized technology for an emerging biopharmaceutical's Phase 2 COVID treatment trial in critically ill patients, minimizing paper data risks and streamlining consent and data management across multiple sites and solutions.
-
Consolidating Clinical Supply Chain Operations With GxP Inventory
A Japan-based biotechnology company leveraged Signant SmartSignals® GxP Inventory, which improved visibility, reduced risks and costs, and optimized operations in this case study.
-
RTSM: Randomization And Cohort Management, IP Inventory Management
Signant’s SmartSignals® RTSM solution helped an innovative biopharmaceutical company secure an FDA Orphan Drug designation for its cardiomyopathy drug.
-
Unified Platform Supports Rapid Implementation Of Rescue Study
Explore how these integrated solutions helped an emerging biopharma to implement a plan for study build and migration with minimal disruption to sites.
CONTACT INFORMATION
Signant Health
785 Arbor Way
Blue Bell, PA 19422
UNITED STATES
Phone: 610.400.4141